Early Results from CAR T-Cell Therapy Trial for Myeloma Demonstrate “Encouraging” Response Rates

In an ongoing, phase I trial of chimeric antigen receptor (CAR) T-cell therapy in patients with relapsed/refractory myeloma, thirty three out of thirty five patients achieved finish response (CR) or very good partial response (VGPR), for a clinical remission rate of ninety four percent. Read More